| Cat.No. | Name | Information |
|---|---|---|
| M1579 | Naloxone | Naloxone is an opioid inverse agonist used to counter the effects of opiate overdose. |
| M9615 | DAMGO | DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents, Kd value is 3.46 nM for native μ-OPR. |
| M7014 | Naltrindole hydrochloride | Naltrindole hydrochloride is a selective non-peptide δ opioid antagonist (Ki = 0.02-0.3 nM), with much lower affinities for κ- and µ-opioid receptors (Kis = 10-66 and 6-64 nM, respectively). Naltrindole hydrochloride can cross the blood-brain barrier. |
| M31390 | TRV250 | TRV250 is a novel delta-like opioid receptor (DOR) small molecule agonist that preferentially selects G-protein signaling with relatively little activation of the β-arrestin2 post-receptor signaling pathway. |
| M30898 | Naldemedine | Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CLpro encoded by SARS-CoV2 genome. |
| M30824 | TAN-452 | TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control. |
| M30799 | Naloxonazine dihydrochloride | Naloxonazine dihydrochloride is a specific μ-opioid receptor antagonist with an IC50 of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity. |
| M30655 | Naloxonazine | Naloxonazine is a potent and selective opiate mu-1 antagonist that can also affect leishmania by regulating host coding function. |
| M30361 | MT-7716 free base | MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention. |
| M29719 | Anrikefon acetate | Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect. |
| M29333 | (±)-J-113397 | (±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ. |
| M29229 | AT-121 | AT-121 is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects. |
| M28848 | BMS-986188 | BMS-986188 is a selective positive allosteric modulator of δ-opioid receptor with an EC50 of 0.05 μM. |
| M28824 | Nociceptin | Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic. |
| M28209 | LY2444296 | LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects. |
| M28208 | Naldemedine tosylate | Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. |
| M28066 | KNT-127 | KNT-127 is a potent and selective δ-opioid receptor agonist effective by systemic administration. KNT-127 shows selectivity for the δ-receptor (Ki 0f 21.3, 0.16, 153 nM for opioid μ-, δ-, and κ-receptors, respectively). KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. |
| M28028 | Enadoline hydrochloride | Enadoline (CI-977) hydrochloride is a highly selective, brain-penetrating, and nonpeptide kappa-opioid receptor (KOR) agonist (Ki=1.25 nM). Antinociceptive effects. |
| M28027 | Enadoline | Enadoline (CI-977) is a highly selective, brain-penetrating, and nonpeptide kappa-opioid receptor (KOR) agonist (Ki=1.25 nM). Antinociceptive effects. |
| M27965 | TAN-67 dihydrobromide | TAN-67 (SB-205607) dihydrobromide is a potent and selective nonpeptidic δ-opioid receptor agonist with a Ki value of 0.647 nM. TAN-67 dihydrobromide has neuroprotective effect. TAN-67 dihydrobromide can be used in research of ischemic stroke. |
| M27962 | MT-7716 hydrochloride | MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention. |
| M27855 | ICI 199441 | ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion. |
| M21657 | Bevenopran | Bevenopran (CB-5945) is a peripheral μ-opioid receptor antagonist. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
